Clinical Trial Update: Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating efficacy and safety of secukinumab in non-radiographic axial spondyloarthritis has completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-radiographic Spondyloarthritis

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-radiographic Spondyloarthritis | Phase 3 | Status: COMPLETED | Results posted: 2020-08-07